Tilray Shares Surge on Product Launch and Regulatory Speculation

Tilray Brands, Inc. saw its share price skyrocket in pre-market trading Friday, recording gains between 27% and 30%. The stock, which had closed the previous session at $8.43, climbed to an intraday high of $11.09. This significant rally is being driven by a dual catalyst: the strategic launch of a new premium cannabis product in Canada and emerging reports suggesting the Trump administration may be considering a reclassification of marijuana under U.S. federal law.

Regulatory Winds Shift in the United States

Market sentiment received a substantial boost from political developments. Credible sources indicate that U.S. President Donald Trump may direct federal agencies to downgrade marijuana from a Schedule I to a Schedule III controlled substance. Such a move would carry profound implications for cannabis companies like Tilray.

A reclassification would likely provide critical tax relief by eliminating the burdensome Section 280E, thereby allowing businesses to deduct ordinary operating expenses. Furthermore, a Schedule III status typically reduces barriers for institutional investors and facilitates access to essential banking services, potentially unlocking new capital streams.

Strategic Product Expansion in Canada

Concurrently, a concrete operational development is fueling investor optimism. The company’s subsidiary, Redecan, has launched a new line of premium vaporizer products, marking its first entry into the high-growth live resin liquid diamond category.

The “Amped Live Resin Liquid Diamond” vape cartridges feature two distinct strains: Space Age CK and Blueberry DNTS. According to the manufacturer, the formula blends 80% “Legit Live Resin” with 20% “Liquid Diamonds” to create a full-spectrum cannabinoid profile. The hardware utilizes “TrueDraw Ceramic” cores made from medical-grade zirconia, designed to prevent clogging.

Should investors sell immediately? Or is it worth buying Tilray?

The launch timing is strategic, targeting the winter season from December through February. Internal Tilray data identifies this period as having the highest consumer demand for vape products within the Canadian market.

Market Reaction and Financial Context

The sharp price movement was accompanied by heavy trading volume. Despite the impressive single-day surge, the stock remains down approximately 36% for the year 2025. The pre-market advance pushed Tilray’s market capitalization back toward the $1 billion threshold, with estimates placing it between $950 million and $980 million following the jump.

This shifting landscape has prompted analysts at ATB Capital Markets to revise their stance on the stock, upgrading their rating from “Strong Sell” to “Hold.” The adjustment reflects an evolving risk-reward profile, acknowledging Tilray’s ongoing diversification efforts and the potential for positive regulatory changes in the United States.

The convergence of a tangible product innovation and high-stakes regulatory speculation has placed Tilray in a notably volatile position. Investors are currently pricing in the potential for improved margins from the new vape line and the prospect of a significantly reduced tax burden. The coming weeks will be crucial in determining whether the Trump administration follows through on the reported plans and if Tilray can operationally deliver on the heightened market expectations.